Neurophet, an artificial intelligence (AI) solution company for brain disorder diagnosis and treatment, announced a partnership with RapidAI, a global leader in enterprise clinical AI, to integrate Neurophet's advanced neurodegenerative brain imaging solutions into the Rapid Enterprise Platform.

Backed by deep clinical expertise in neurosciences, RapidAI's enterprise platform combines advanced imaging AI with workflow solutions that connect radiology and clinical teams throughout the patient journey. RapidAI's solutions are trusted by more than 2,500 hospitals across 100 countries worldwide.

The partnership will accelerate commercialization of the globally established Neurophet solution into the U.S. market by integrating into RapidAI's platform. The Neurophet comprehensive brain imaging analysis solution includes Neurophet AQUA AD Plus and Neurophet SCALE PET, designed to support the prescription of Alzheimer's disease treatments, brain health, and dementia patient management.

The portfolio also includes Neurophet AQUA MS, a quantitative imaging analysis software solution for multiple sclerosis (MS). Integrated into Neurophet AQUA, Neurophet AQUA MS analyzes brain images of patients with MS, an intractable disease of the central nervous system.

Neurophet AQUA AD Plus uses AI-powered brain magnetic resonance imaging (MRI) analysis to automatically identify and quantify the locations and number of hypointense lesions associated with cerebral microbleeds and superficial siderosis, as well as hyperintense lesions associated with brain edema.

These imaging findings are particularly important for monitoring potential treatment-related side effects in patients with Alzheimer's disease receiving anti-amyloid therapies, such as Leqembi and Kisunla. By providing quantitative insights into these brain changes, the solution seeks to support clinicians in assessing treatment safety and making more informed decisions throughout the course of Alzheimer's disease treatment.

By combining RapidAI's established U.S. hospital and healthcare customer base with Neurophet's AI-powered brain imaging technology, the companies aim to expand access to advanced neuroimaging solutions and support more informed clinical decision-making.

"We plan to complete the integration of Neurophet AQUA AD Plus into RapidAI and begin full-scale product distribution, focusing on memory disorders centers in the U.S. that prescribe Leqembi and Kisunla," said Jake Junkil Been, Co-CEO of Neurophet.

He added, "We will further expand the platform integration to include Neurophet AQUA and Neurophet SCALE PET, establishing a comprehensive solution delivery framework that covers the entire continuum of dementia care, from diagnosis to treatment monitoring."